Financials in USD. Standardized financial statements.
A compact view of how Clearside Biomedical, Inc. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.66M | $8.23M | $1.33M | $29.57M | $7.89M | $2.17M | $30,000 | $345,000 | $520,000 | $0 |
| Revenue Growth? | -79.8% | +519.9% | -95.5% | +274.7% | +263.3% | +7143.3% | -91.3% | -33.7% | 0.0% | 0.0% |
| Cost of Revenue? | $149,000 | $355,000 | $204,000 | $0 | $0 | $0 | $0 | $0 | $0 | $33,000 |
| Gross Profit? | $1.51M | $7.87M | $1.12M | $29.57M | $7.89M | $2.17M | $30,000 | $345,000 | $520,000 | -$33,000 |
| Gross Margin? | +91.0% | +95.7% | +84.6% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | 0.0% |
| Operating Expenses? | $30.40M | $32.72M | $31.40M | $30.20M | $25.83M | $32.48M | $82.97M | $58.75M | $25.72M | $17.32M |
| Operating Income? | -$28.88M | -$24.84M | -$30.28M | -$627,000 | -$17.93M | -$30.30M | -$82.94M | -$58.41M | -$25.20M | -$17.32M |
| EBITDA? | -$24.35M | -$23.06M | -$29.46M | $554,000 | -$17.70M | -$30.09M | -$82.76M | -$58.23M | -$25.13M | -$17.26M |
| Income Before Tax | -$34.35M | -$32.48M | -$32.95M | $376,000 | -$18.21M | -$30.77M | -$82.82M | -$58.98M | -$25.88M | -$17.64M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $127,000 | -$182,000 | -$65,000 | $8,000 |
| Net Income? | -$34.35M | -$32.48M | -$32.95M | $376,000 | -$18.21M | -$30.77M | -$82.82M | -$58.98M | -$25.88M | -$17.64M |
| EPS? | $-7.05 | $-7.95 | $-8.25 | $0.10 | $-5.85 | $-12.00 | $-40.35 | $-34.95 | $-29.55 | $-21.60 |
| Diluted EPS? | $-7.05 | $-7.95 | $-8.25 | $0.09 | $-5.85 | $-12.00 | $-40.35 | $-34.95 | $-29.55 | $-21.60 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality